NL-201

NL-201

NL-201

Immunotherapy drug candidate that underwent a Phase 1 human clinical trial in cancer patients

NL-201 was an immunotherapy drug candidate that underwent a Phase 1 human clinical trial in cancer patients.[1] It is a de novo protein that was first computationally designed at the Institute of Protein Design (IPD), University of Washington.[2] In November 2022, Neoleukin Therapeutics announced it would discontinue the development of NL-201.[3]

History

The predecessor of NL-201, neoleukin-2/15, was first described and published on Nature magazine in January 2019.[2] The citizen science distributed computing project Rosetta@home, based at the University of Washington, contributed with "forward folding" experiments that helped validate protein designs of neoleukin-2/15, from which NL-201 was further developed by Neoleukin Therapeutics, a biopharmaceutical company that originated at the IPD.[4][5]

The Phase 1 human clinical trial began on May 5, 2021.[6]

In January 2022, Neoleukin Therapeutics announced a collaboration with Merck for a combination clinical trial of Merck's Pembrolizumab and Neoleukin's NL-201.[7]

In November 2022, Neoleukin Therapeutics announced it would discontinue the development of NL-201.[3]

References

  1. [1]
    Neoleukin Therapeutics, Inc. (2021-05-25). "A First-in-Human Phase 1 Study of NL-201 in Patients With Relapsed or Refractory Cancer". {{cite journal}}: Cite journal requires |journal= (help)
  2. [2]
    Silva, Daniel-Adriano; Yu, Shawn; Ulge, Umut Y.; Spangler, Jamie B.; Jude, Kevin M.; Labão-Almeida, Carlos; Ali, Lestat R.; Quijano-Rubio, Alfredo; Ruterbusch, Mikel; Leung, Isabel; Biary, Tamara (2019-01-09). "De novo design of potent and selective mimics of IL-2 and IL-15". Nature. 565 (7738): 186–191. Bibcode:2019Natur.565..186S. doi:10.1038/s41586-018-0830-7. ISSN 1476-4687. PMC 6521699. PMID 30626941.
  3. [3]
    "Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update". 2022-11-14.
  4. [4]
    "Another publication in Nature describing the first de novo designed proteins with anti-cancer activity". boinc.bakerlab.org. Retrieved 2021-06-22.
  5. [5]
    Therapeutics, Neoleukin (June 2020). "NL-201: A de novo CD25-independent combined IL-2 and IL-15 receptor agonistdesigned to selectively stimulate anti-tumor CD8+ effector T and NK cells" (PDF). Neoleukin Therapeutics. Retrieved 2021-06-22.
  6. [6]
    "Neoleukin Therapeutics Announces Initiation of Phase 1 NL-201 Trial | Neoleukin Therapeutics, Inc". investor.neoleukin.com. Retrieved 2021-06-22.
  7. [7]
    "Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with KEYTRUDA® (pembrolizumab) | Neoleukin Therapeutics, Inc". investor.neoleukin.com. Retrieved 2022-01-10.


Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article NL-201, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.